# Saudi HTA July 2025: Gulf & Global Pricing Implications

> Saudi Arabia’s move towards economic evaluation adds a value-based layer to a market already influential through IRP and Gulf procurement.

Canonical: https://goldentriangleconsultants.com/news-and-insights/f/saudi-hta-july-2025-gulf-global-pricing-implications/

Date: 15 July 2025

Saudi Arabia’s move towards mandatory economic evaluation adds a value-based layer to a market already influential through IRP and Gulf procurement.

From July 2025, Saudi Arabia’s pricing environment entered an important new phase as economic evaluation became a more formal part of the route to a price certificate for new medicines. For global pricing teams, the significance goes well beyond one market.

Saudi Arabia is already influential across the Gulf. Its prices interact with International Reference Pricing (IRP), regional procurement and neighbouring pricing systems, which means an HTA-driven change in the Saudi price can have consequences well outside the Kingdom.

## Value assessment now sits alongside external referencing

The key strategic development is the combination of two different pricing logics. Economic evaluation asks whether the requested price represents acceptable value given the clinical benefit and costs. IRP, by contrast, benchmarks against prices observed in other countries.

When these mechanisms operate together, manufacturers need to consider both the value-based case for a Saudi price and the international price corridor around that price. A price that is difficult to support economically may require negotiation or adjustment before the downstream IRP effects are even considered.

## Why the regional impact matters

A lower Saudi price can become a tighter anchor for other Gulf and Middle Eastern markets. It can also affect regional tender expectations and influence countries that directly or indirectly monitor Saudi prices when establishing their own ceilings.

This makes Saudi launch planning increasingly interconnected with launch order, reference baskets and the timing of price visibility. A concession that is manageable in Saudi Arabia in isolation may be substantially more expensive when its potential effect across referenced markets is included.

## Implications for global pricing teams

Companies should pressure-test Saudi scenarios before submission rather than treating HTA as a local evidence exercise. The modelling should consider the requested Saudi price, plausible negotiated outcomes, the markets that may reference Saudi Arabia and the timing with which any new price could flow through external-reference systems.

It is also important to distinguish visible list-price effects from confidential net arrangements. Where value is addressed through confidential mechanisms, the global implications can be very different from a formal change to the public price certificate.

## A broader signal

Saudi Arabia’s approach reflects a wider trend: emerging and middle-income markets are combining pharmacoeconomic assessment with established price referencing and procurement mechanisms. That creates a more complex global pricing environment in which HTA, IRP and contracting have to be analysed together.

For manufacturers, robust country-specific economic models and global IRP scenario tools are therefore becoming complementary capabilities rather than separate disciplines.

*This article reflects the market and policy context at the date of publication.*

## Further reading

- [Saudi Food & Drug Authority](https://www.sfda.gov.sa/en)
- [Gulf Health Council](https://ghc.sa/en/)
## Need to model the global pricing impact?

Golden Triangle Consultants develops bespoke pricing, market access and IRP tools to help teams test launch, price and revenue scenarios.